Long Term Eslicarbazepine Acetate Extension Study
Long Term Eslicarbazepine Acetate Extension Study
This is a long term, open-label, safety extension study in subjects with partial onset seizures.
This is a long term, multicenter, open-label, safety extension study in subjects with partial onset seizures who have just completed, discontinued, or exited the 18-week treatment phase of Protocols 093-045 or 093-046. The initial study duration is 1 year with the option of continuing study drug treatment post 1 year until a subject discontinues study, the study drug becomes clinically available in the subject's locale, or the sponsor terminates the study drug clinical development program.
This study was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
Subject Inclusion/Exclusion Criteria:
For subjects to continue into the post 1 year part of the study, subjects must, in the opinion of the Investigator (with consultation with Medical Monitor, as appropriate), continue to potentially benefit from continued study participation and have no new medical conditions that would preclude study participation.
Loma Linda, California 92354, United States
Chesterfield, Missouri 63017, United States
Philadelphia, Pennsylvania 19140, United States
Blagoevgrad, 2700, Bulgaria
Pleven, 5800, Bulgaria
Varna, 9000, Bulgaria
Koty, Zlín 760 01, Czechia
Belgrade, 11 000, Serbia
Dnipropetrovsk, 49005, Ukraine
Donetsk, 83008, Ukraine
Kharkiv, 61018, Ukraine
Kharkiv, 61068, Ukraine
Kharkiv, 61153, Ukraine
Kiev, 01030, Ukraine
Odesa, 65006, Ukraine